15-keto-13-14-dihydroprostaglandin-f2alpha and Urogenital-Neoplasms

Prostaglandin F2 alpha can be measured as a stable degradation product, 13,14-dihydro-15-keto-prostaglandin F2 alpha (DHK-PGF2 alpha). Pathological serum levels of this lipid compound have been observed in prostate hyperplasia and treated testicular cancer patients. In renal cancer patients elevated DHK-PGF2 alpha shows a trend to normalize 12 months following nephrectomy in stage T0N0M0. Bladder cancer patients have slightly increased DHK-PGF2 alpha that differ in relation to preinvasive bladder cancer. In contrast serum haptoglobin levels were significantly pathological in patients with kidney and bladder cancer, suggesting involved cancer metabolism. Patients with prostate and testis cancer are without distinct relation to the tumour stage. After specification of haptoglobin types no coincidence to urogenital tumours could be detected. Correlated aberration of PGF2 alpha and haptoglobin displayed different patterns depending on the type of urogenital tumour.

Topics: Adult; Aged; Dinoprost; Female; Haptoglobins; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostaglandins F; Prostatic Hyperplasia; Prostatic Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms

13,14-Dihydro-15-keto-prostaglandin F2 alpha (13,14-DHK-PGF2 alpha) represents a stable product of degradation after pulmonary flow and it is shown to be reliably measured by radioimmunoassay. In patients with urogenital tumors, serum levels of 13,14-DHK-PGF2 alpha are distinctly elevated when compared to a control group. The rate of synthesis of this compound in urogenital tumors, however, appears to be different.

Topics: Adenocarcinoma; Dinoprost; Female; Humans; Kidney Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Prostaglandins F; Prostatic Hyperplasia; Prostatic Neoplasms; Radioimmunoassay; Testicular Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms